Physician profile
Daryn Abraham
NPI 1104975770
$6,032.59
in general payments reported to CMS, 2019-2025
23 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $569 · 2021: $372 · 2022: $366 · 2023: $362 · 2024: $1,472 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.75 |
| Education | $246.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,038.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $795.13 | 2019-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $596.14 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $502.11 | 2019-2024 | Xolair |
| Glaxosmithkline, LLC. | $467.74 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $413.52 | 2022-2025 | Tezspire |
| Aerin Medical INC. | $405.12 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $314.81 | 2019-2025 | |
| Novo Nordisk INC | $311.84 | 2022-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.17 | 2019-2023 | Jardiance |
| Shire North American Group INC | $213.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $123.38 | 2021 | |
| Edwards Lifesciences Corporation | $107.98 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kaleo, INC. | $95.55 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $76.35 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $71.64 | 2021-2025 | Hizentra |
| Integra Lifesciences Corporation | $58.52 | 2024-2025 | Acclarent Aera, Inspira Air, Relieva Spinplus Nav |
| Takeda Pharmaceuticals U.S.A., INC. | $47.25 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.36 | 2019 | |
| Abbvie INC. | $28.07 | 2022 | |
| Hospira, INC. | $26.27 | 2024 | |
| Smith+Nephew, INC. | $23.09 | 2024 | |
| Alk-Abello, INC | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryn Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.